NZ592545A - Anti-ferroportin 1 monoclonal antibodies and uses thereof - Google Patents
Anti-ferroportin 1 monoclonal antibodies and uses thereofInfo
- Publication number
- NZ592545A NZ592545A NZ592545A NZ59254509A NZ592545A NZ 592545 A NZ592545 A NZ 592545A NZ 592545 A NZ592545 A NZ 592545A NZ 59254509 A NZ59254509 A NZ 59254509A NZ 592545 A NZ592545 A NZ 592545A
- Authority
- NZ
- New Zealand
- Prior art keywords
- seq
- nos
- antibody
- ferroportin
- monoclonal antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12007608P | 2008-12-05 | 2008-12-05 | |
| US23981809P | 2009-09-04 | 2009-09-04 | |
| PCT/US2009/066187 WO2010065496A1 (en) | 2008-12-05 | 2009-12-01 | Anti-ferroportin 1 monoclonal antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ592545A true NZ592545A (en) | 2012-12-21 |
Family
ID=41683589
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ592545A NZ592545A (en) | 2008-12-05 | 2009-12-01 | Anti-ferroportin 1 monoclonal antibodies and uses thereof |
Country Status (25)
| Country | Link |
|---|---|
| EP (1) | EP2373335B1 (enExample) |
| JP (1) | JP5713917B2 (enExample) |
| KR (1) | KR101353117B1 (enExample) |
| CN (1) | CN102238962B (enExample) |
| AR (1) | AR074398A1 (enExample) |
| AU (1) | AU2009322587B2 (enExample) |
| BR (1) | BRPI0922288A2 (enExample) |
| CA (1) | CA2745618C (enExample) |
| CY (1) | CY1117355T1 (enExample) |
| DK (1) | DK2373335T3 (enExample) |
| EA (1) | EA020472B1 (enExample) |
| ES (1) | ES2566343T3 (enExample) |
| HR (1) | HRP20160302T1 (enExample) |
| HU (1) | HUE028585T2 (enExample) |
| IL (1) | IL212731A0 (enExample) |
| MX (1) | MX2011005939A (enExample) |
| NZ (1) | NZ592545A (enExample) |
| PA (1) | PA8849601A1 (enExample) |
| PL (1) | PL2373335T3 (enExample) |
| SG (1) | SG171960A1 (enExample) |
| SI (1) | SI2373335T1 (enExample) |
| TW (1) | TW201023891A (enExample) |
| UA (1) | UA104741C2 (enExample) |
| WO (1) | WO2010065496A1 (enExample) |
| ZA (1) | ZA201103941B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112014027905A2 (pt) * | 2012-05-14 | 2017-06-27 | Genentech Inc | anticorpo, célula, ácido nucleico, métodos de identificação de um primeiro anticorpo, de inibição do crescimento de uma célula, de tratamento terapêutico, de determinação da presença de uma proteína, de diagnóstico da presença de um tumor e de distribuição de agente citotóxico. |
| WO2019213016A1 (en) | 2018-04-30 | 2019-11-07 | The Children's Hospital Of Philadelphia | Methods of improving anemias by combining agents |
| CA3156007A1 (en) | 2019-09-27 | 2021-04-01 | Disc Medicine, Inc. | METHODS OF TREATING MYELOFIBROSE AND ASSOCIATED CONDITIONS |
| CN110806486B (zh) * | 2019-11-23 | 2023-03-21 | 中南大学湘雅三医院 | Mafg/as1/pcbp2/fpn1调控轴作为靶位点检测试剂的应用 |
| AU2021273014A1 (en) | 2020-05-13 | 2022-11-17 | AbbVie Deutschland GmbH & Co. KG | Anti-hemojuvelin (HJV) antibodies for treating anemia of chronic disease |
| ES3075793T3 (en) | 2020-05-13 | 2026-08-07 | Disc Medicine Inc | Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis |
| CN113980987A (zh) * | 2021-12-06 | 2022-01-28 | 上海市农业科学院 | 一种提高植物抗镍性能的PgIREG1S和AlATP-PRTS双基因组及其应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7166448B1 (en) * | 1999-05-10 | 2007-01-23 | Children's Medical Center Corproation | Ferroportin1 nucleic acids and proteins |
| IT1319221B1 (it) * | 2000-10-17 | 2003-09-26 | Antonello Pietrangelo | Mutazioni nel gene della ferroportina 1 associata ad emocromatosiereditaria. |
| EP2803675A3 (en) * | 2008-01-25 | 2014-12-24 | Amgen, Inc | Ferroportin antibodies and methods of use |
-
2009
- 2009-11-23 PA PA20098849601A patent/PA8849601A1/es unknown
- 2009-11-24 AR ARP090104529A patent/AR074398A1/es unknown
- 2009-11-25 TW TW098140185A patent/TW201023891A/zh unknown
- 2009-12-01 DK DK09760073.8T patent/DK2373335T3/en active
- 2009-12-01 EA EA201170764A patent/EA020472B1/ru not_active IP Right Cessation
- 2009-12-01 MX MX2011005939A patent/MX2011005939A/es active IP Right Grant
- 2009-12-01 ES ES09760073.8T patent/ES2566343T3/es active Active
- 2009-12-01 UA UAA201107028A patent/UA104741C2/uk unknown
- 2009-12-01 KR KR1020117014053A patent/KR101353117B1/ko not_active Expired - Fee Related
- 2009-12-01 JP JP2011539625A patent/JP5713917B2/ja not_active Expired - Fee Related
- 2009-12-01 BR BRPI0922288A patent/BRPI0922288A2/pt not_active IP Right Cessation
- 2009-12-01 SG SG2011040797A patent/SG171960A1/en unknown
- 2009-12-01 NZ NZ592545A patent/NZ592545A/xx not_active IP Right Cessation
- 2009-12-01 AU AU2009322587A patent/AU2009322587B2/en not_active Ceased
- 2009-12-01 EP EP09760073.8A patent/EP2373335B1/en active Active
- 2009-12-01 SI SI200931382T patent/SI2373335T1/sl unknown
- 2009-12-01 PL PL09760073T patent/PL2373335T3/pl unknown
- 2009-12-01 CN CN200980148354.8A patent/CN102238962B/zh not_active Expired - Fee Related
- 2009-12-01 WO PCT/US2009/066187 patent/WO2010065496A1/en not_active Ceased
- 2009-12-01 HR HRP20160302TT patent/HRP20160302T1/hr unknown
- 2009-12-01 CA CA2745618A patent/CA2745618C/en not_active Expired - Fee Related
- 2009-12-01 HU HUE09760073A patent/HUE028585T2/en unknown
-
2011
- 2011-05-05 IL IL212731A patent/IL212731A0/en unknown
- 2011-05-27 ZA ZA2011/03941A patent/ZA201103941B/en unknown
-
2016
- 2016-04-12 CY CY20161100296T patent/CY1117355T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010065496A1 (en) | 2010-06-10 |
| AR074398A1 (es) | 2011-01-12 |
| JP2012510814A (ja) | 2012-05-17 |
| CA2745618C (en) | 2014-06-10 |
| JP5713917B2 (ja) | 2015-05-07 |
| CA2745618A1 (en) | 2010-06-10 |
| AU2009322587A1 (en) | 2011-07-28 |
| EA201170764A1 (ru) | 2011-12-30 |
| HUE028585T2 (en) | 2016-12-28 |
| HK1158977A1 (zh) | 2012-07-27 |
| KR20110084996A (ko) | 2011-07-26 |
| UA104741C2 (uk) | 2014-03-11 |
| AU2009322587B2 (en) | 2013-09-26 |
| CN102238962A (zh) | 2011-11-09 |
| SG171960A1 (en) | 2011-07-28 |
| KR101353117B1 (ko) | 2014-02-17 |
| EP2373335A1 (en) | 2011-10-12 |
| MX2011005939A (es) | 2011-06-27 |
| IL212731A0 (en) | 2011-07-31 |
| TW201023891A (en) | 2010-07-01 |
| PL2373335T3 (pl) | 2016-08-31 |
| SI2373335T1 (sl) | 2016-04-29 |
| HRP20160302T1 (hr) | 2016-04-22 |
| EA020472B1 (ru) | 2014-11-28 |
| ES2566343T3 (es) | 2016-04-12 |
| BRPI0922288A2 (pt) | 2018-08-28 |
| DK2373335T3 (en) | 2016-05-02 |
| CN102238962B (zh) | 2014-02-12 |
| ZA201103941B (en) | 2012-11-28 |
| PA8849601A1 (es) | 2010-07-27 |
| EP2373335B1 (en) | 2016-02-24 |
| CY1117355T1 (el) | 2017-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JO2828B1 (en) | Anti-Hepsidine antibodies and their uses | |
| NZ594466A (en) | Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies | |
| NZ594682A (en) | Fully human antibodies specific to cadm1 | |
| NZ610294A (en) | Human antibodies to human tnf-like ligand 1a (tl1a) | |
| NZ592215A (en) | c-MET ANTIBODIES | |
| NZ590863A (en) | Anti-hepcidin-25 selective antibodies and uses thereof | |
| PE20141151A1 (es) | Proteinas de union al antigeno cd27l | |
| NZ602220A (en) | Antibodies with ph dependent antigen binding | |
| UA106607C2 (uk) | Білки специфічного зв'язування і їх застосування | |
| PH12016501691A1 (en) | Antibodies to matrix metalloproteinase 9 | |
| NZ610091A (en) | Antibodies | |
| NZ598194A (en) | Anti-cmet antibody and its use for the detection and the diagnosis of cancer | |
| NZ623319A (en) | Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
| NZ593289A (en) | Anti-neuropilin-1 antibodies for treating angiogenesis | |
| SG170728A1 (en) | Anti-tumor cell antigen antibody therapeutics | |
| WO2007133822A8 (en) | Gitr antibodies for the treatment of cancer | |
| NZ600768A (en) | Human antibodies to human angiopoietin-like protein 4 | |
| NZ603492A (en) | Humanized anti-factor d antibodies and uses thereof | |
| EA032189B9 (ru) | Изолированные человеческие моноклональные антитела против ингибитора пути тканевого фактора (tfpi) и фармацевтическая композиция, содержащая их | |
| EP2210939A4 (en) | Anti-bst2 antibody | |
| SG156668A1 (en) | Angiopoietin-2 specific binding agents | |
| WO2008118733A3 (en) | Methods of treating cancer by administering human il-18 combinations | |
| UA104741C2 (uk) | Моноклональні антитіла проти феропортину 1 та варіанти їх застосування | |
| JP2012510814A5 (enExample) | ||
| WO2007067984A3 (en) | Neutralizing antibodies against primate psgl-1 and uses therefor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 01 DEC 2016 BY THOMSON REUTERS Effective date: 20130920 |
|
| LAPS | Patent lapsed |